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Background: Numerous national guidelines have been issued to assist
general practitioners’ safe analgesic prescribing. Their effectiveness is
unclear. The objective of this study was to examine trends in general
practitioners’ prescribing behaviour in relation to national guidelines.
Methods: This was a retrospective observational database study of
registered adult patients prescribed an analgesic (2002–2009) from the
Consultations in Primary Care Archive – 12 North Staffordshire general
practices. Prescribing guidance from the UK Medicines Regulatory Health
Authority (MHRA) regarding non-steroidal anti-inflammatory drugs
(NSAIDs) and co-proxamol, and the National Institute for Health and
Clinical Excellence (NICE) osteoarthritis (OA) management guidelines
were considered. Analgesic prescribing rates were examined, arranged
according to a classification of six equipotent medication groups: (1) basic
analgesics; (2)–(5) increasingly potent opioids and (6) NSAIDs. In each
quarter from 2002 to 2009, the number of patients per 10,000 registered
population receiving a prescription for the first time from each group was
determined. Quarters associated with significant changes in the underlying
prescribing trend were determined using joinpoint regression.
Results: A significant decrease in incident co-proxamol and Cox-2
prescribing occurred around the time of the first MHRA advice to stop
using them and were rarely prescribed thereafter. The new prescribing of
weak analgesics (e.g., co-codamol 8/500) increased at this same time.
Initiating topical NSAIDs significantly increased around the time of the
NICE OA guidelines.
Conclusions: Significant prescribing changes occurred when national
advice and guidelines were issued. The effectiveness of this advice may vary
depending upon the content and method of dissemination. Further evalu-
ation of the optimal methods for delivering prescribing guidance is required.
1. Introduction
General practitioners (GPs) are subjected to external
influences that might change their prescribing behav-
iour. These include research publications, pharmaceu-
tical representatives and local medication formularies
(NHS Stoke on Trent, 2010). Additionally, there are
prescribing guidelines from the National Institute for
Health and Clinical Excellence (NICE, 2010a), or advice
from the Medicines and Healthcare products Regula-
tory Agency (MHRA) in the United Kingdom informing
GPs of ‘preferred’ or ‘recommended’ prescribing.
434 Eur J Pain 17 (2013) 434–443 © 2012 European Federation of International Association for the Study of Pain Chapters
However, the individual GP makes any final prescribing
decision and national guidance may have little influ-
ence on this. Previous studies have shown poor con-
cordance between GP prescribing and national
guidance in areas such as statin prescribing (Mantel-
Teeuwisse et al., 2006). Printed educational materials
have shown only a marginal level of effectiveness in
changing doctors’ practice (Farmer et al., 2008;
Wensing et al., 2010). Conversely, Swedish guidelines
were effective in implementing the prescribing of
disease-modifying anti-rheumatic drugs (Carli et al.,
2008), while in the United States, Food and Drug
Administration Advisory guidance accelerated the
decline in use of antipsychotic drugs in dementia (Kales
et al., 2011). National guidelines include targeted and
specific advice from the MHRA on prescribing of indi-
vidual medications in relation to drug safety, or general
advice on the management of a disease, such as that
issued by NICE. The effectiveness of these different
types of prescribing guidelines is currently uncertain.
Analgesics are commonly prescribed in the United
Kingdom. One study found 10% of all prescriptions in
1 year were for painkillers (Bedson et al., 2010). The
overall 4-week prevalence for any pain symptom has
been estimated at 66% in the general population
(Gureje et al., 1998). Additionally, over €12 billion of
lost employment productivity is related to musculosk-
eletal pain highlighting its economic impact (Bevan
et al., 2009).
The MHRA is required to safeguard public health by
ensuring that medicines are acceptably safe. Since
2004, GPs have been informed by the MHRA of several
evidence-based reviews relating to adverse analgesic
events (MHRA, 2004, 2005a,b, 2006). One related to
the toxicity of co-proxamol in overdose (MHRA,
2005b), others advised against the use of certain non-
steroidal anti-inflammatory drugs (NSAIDs) due to an
apparent increase in the risk for certain patients of
myocardial infarction (MHRA, 2004). The NICE
osteoarthritis (OA) guidelines attempted to rationalize
prescribing for this condition (NICE, 2008). NICE advo-
cated the earlier use of topical NSAIDs, and the appro-
priate use of oral NSAID medications in tailored groups
of patients (NICE, 2008). This was a reversal of guid-
ance from a previous review of NSAIDs by the MHRA in
2004 (MHRA, 2004).
We hypothesized that the national guidance such as
that issued by NICE would be more likely to have a
major impact on prescribing due to its prominence and
construct i.e., based on the best evidence. This study’s
objectives, therefore, were to investigate trends in
analgesic prescribing from 2002 to 2009, a period
during which the MHRA and NICE issued advice
regarding analgesic prescribing, and determine how
prescribing changes related to the different types of
guidance given to GPs.
2. Methods
The study employed the Prescriptions in Primary Care
Archive (PiPCA). PiPCA is a part of the Consultations
in Primary Care Archive (CiPCA). In CiPCA, anony-
mized primary care data has been remotely extracted
from 12 general practices within the Keele GP
Research Partnership (Porcheret et al., 2004). Ethical
approval for CiPCA was granted by the North Stafford-
shire Research Ethics Committee for epidemiological
research. The practices have a research agreement
with Keele and code clinical activity to a high standard
having followed the Keele consultation data audit,
training and validation programme (Porcheret et al.,
2004). The quality of the data is comparable to, or
better than, that of larger national general practice
databases (Jordan et al., 2007). Prescribing and demo-
graphic data from the 12 practices that have contrib-
uted to PiPCA continuously from 2001 to 2009 were
analysed for people aged 15 and over. These practices
are from a mix of more and less deprived areas.
There are in excess of 300 separate analgesic prepa-
rations listed within the British National Formulary
(BNF, 2011). It was therefore, considered necessary to
rationalize all analgesics within the BNF into separate
groups of medications, which were considered equally
effective when treating a given level of pain. These
were then arranged hierarchically according to
increasing analgesic potency. A four-step consensus
exercise was undertaken with five academic and 20
practising GPs using nominal group and Delphi con-
What’s already known about this topic?
• The effectiveness of national guidelines on
modifying prescribing behaviour has been
inconsistent.
• Analgesics are among the commonest prescribed
medications in primary care.
• From 2002 to 2009, several advisory guidelines
on analgesic prescribing have been issued. It is
unknown how effective this guidance has been.
What does this study add?
• Directive guidance on drug safety issues appears
most effective in changing prescribing behaviour.
• Evidence-based national guidelines have a more
limited benefit.
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sensus methods (full methodology available from the
authors) to construct the categorization of analgesics.
The final categorization consisted of six groups, group
1 (basic analgesics including paracetamol), groups 2–4
(increasingly strong opioids used alone or in combina-
tion with paracetamol), group 5 (very strong single
opioids such as morphine) and group 6 (NSAIDs),
which were considered separate to groups 1–5 in
terms of analgesic potency (Fig. 1). This model did not
include medications used in the treatment of neuro-
pathic pain in order maintain consistency with exist-
ing models such as the NICE OA guidelines (NICE,
2008) and the World Health Organization analgesic
ladder (Ehrlich, 2003), which currently do not incor-
porate these medications.
Changes in GP prescribing behaviour in relation to
six major pieces of national guidance were analysed.
As it is difficult to demonstrate the individual effects of
interventions grouped closely together in time, those
within 3 months of each other were grouped together
and considered as a single intervention. The interven-
tions considered in the study are shown in Table 1.
Advice issued by the MHRA is sent on an individual-
ized basis using personal letters to all prescribing
Figure 1 Analgesic categorization for prescribing analgesics and NSAIDs in primary care where n = number of individual prescribable medication within
that group.
Table 1 Intervention groupings in relation to their time of issue.
Intervention Date Content
1 21 December 2004 MHRA. Stop using Cox-2 in patients with IHD. Use lowest dose NSAID (MHRA, 2004).
21 January 2005 MHRA. Withdraw co-proxamol over next 3 years (MHRA, 2005b).
17 February 2005 MHRA. Cox- 2 should not be used in heart disease (MHRA, 2005a).
2 August 2005 MHRA. Use lowest dose NSAID tailored to individual risk proﬁle (MHRA, 2005c).
3 October 2006 MHRA. Non-selective NSAIDs may be associated with a small increased risk of thrombotic events (MHRA, 2006).
4 February 2008 NICE OA management guidelines issued (NICE, 2008).
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doctors ensuring that all GPs are aware of the changes
suggested in analgesic use. NICE also disseminate their
guidelines to specific groups that include all GPs.
(NICE, 2010b).
2.1 Annual prescription prevalence
All adults aged 15 and over with a recorded prescrip-
tion for a pain medication from 2001 to 2009 were
identified. Then, annual prescription prevalence was
calculated per 10,000 registered population for each
analgesic group, with 95% confidence interval. The
numerators for calculating annual prescription preva-
lence were the number of patients receiving at least
one prescription within a group within each calendar
year. Repeat or multiple prescriptions in the same
group following the first prescription for a medication
in that group in each year were ignored. The denomi-
nators were the mid-year adult population registration
figures over the 12 registered practices for each year.
The total registered population aged 15 and over of the
practices ranged from 84,064 (2005) to 88,069 (2008)
but the age/sex distribution did not vary. Across all
years, 22% were aged 65 and over and 51% were
female. Hence, it was not felt necessary to standardize
the prevalence figures.
2.2 Effect of interventions on new prescribing
Each year was divided into quarterly time periods and
the number of people prescribed at least one new
analgesic within an analgesic group was extracted for
each time period from 2002 to 2009. A new analgesic
was defined as no previous analgesic prescription
issued from within the same group in the previous
12 months. The quarters were defined on a seasonal
basis from the second quarter of 2002 (comprising
March, April and May) to the last quarter of 2009
(September, October and November); for easy distinc-
tion, the quarters are labelled 2002q2 to 2009q4. The
Quality and Outcomes Framework contained in the
new General Medical Services contract for GPs in the
United Kingdom requires GPs to review their patient’s
repeat prescriptions on an annual basis (Department
of Health, 2012). Consequently, we have considered
January 2001 to February 2002 as a run in period for
the study since this then decreases the prospect of
including repeat prescriptions in the analysis. The
quarterly number of people per 10,000 registered
population receiving a drug in each group who had
not received a drug from this group in the 12 months
prior to that quarter was determined. The denomina-
tors were the mid-year adult populations. In view of
the specific nature of the interventions relating par-
ticularly to Cox-2 inhibitors (intervention 1), topical
NSAIDs (intervention 4) and co-proxamol (interven-
tion 1), these subgroups were also analysed separately.
The four interventions (Table 1) occurred at time
points 2005 quarter 1 (q1), 2005q3, 2006q4 and
2008q1 splitting the 8 years into five segments.
2.3 Statistical analysis
Joinpoint regression was used to identify quarters
where a marked change (the ‘joinpoint’) in the under-
lying trend in the incidence of new prescriptions
occurred for each group of analgesia (Kim et al., 2000;
Fay et al., 2006; National Cancer Institute, 2011). Per-
mutation tests using Monte Carlo methods were used
to determine the minimum number of joinpoints
required to provide an adequate fit to the data. A
significance level of 1% was used to assess the need for
each extra joinpoint, starting from zero joinpoints. The
final model consists of a series of linear lines with
different slopes connected together at the joinpoints.
The time point for the start of each identified change
in the underlying prescribing trend (the joinpoint) can
then be compared with the dates of the interventions.
If no joinpoints were identified, this would indicate no
significant change in the underlying trend in prescrib-
ing between 2002 and 2009. Models were fitted using
the joinpoint regression program (National Cancer
Institute, 2011).
3. Results
3.1 Annual prescription prevalence
Annual prescription prevalences between 2001 and
2009 are given in Supporting Information Table S1.
The annual prescription prevalence of all analgesics
remained stable at around 3100 patients prescribed at
least 1 analgesic per 10,000 registered population
annually. Prescribing of moderate analgesics fell by
two-thirds from 754/10,000 in 2001 to 230/10,000 in
2006 before increasing to 287/10,000 in 2009.
Co-proxamol prescriptions fell from 736/10,000 in
2001 to 11/10,000 in 2009. Prevalence of Cox-2
inhibitor prescribing more than doubled from 167
patients/10,000 in 2001 to 378/10,000 in 2004 but
then fell to 65/10,000 by 2009. By contrast, the
number of people prescribed topical NSAIDs more
than doubled over the time period (from 272/10,000
in 2001 to 602/10,000 in 2009). Prescribing of strong
analgesics (507/10,000 to 955/10,000) and very
strong analgesics (38/10,000 to 74/10,000) almost
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doubled from 2001 to 2009. There were smaller
increases for basic and weak analgesics.
3.2 Effect of interventions on new
analgesic prescribing
Fig. 2 shows the trends in new analgesic prescribing
over the period 2002–2009 for each of the six main
groups of analgesia. Particularly noticeable are the
sharp fall in number of people newly prescribed mod-
erate analgesics and the decline in NSAID prescribing
around the time of intervention 1 with increases in
new weak and strong analgesic prescribing.
Fig. 3 illustrates the temporal relationship between
significant joinpoint quarters, changes in analgesic
prescribing and national prescribing interventions
Figure 2 Incident number of patients per
10,000 registered population prescribed an
analgesic from the six groups per quarter.
Figure 3 Signiﬁcant changes in trends in new analgesic prescribing and time of national prescribing interventions 2002–2009.
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from 2002 to 2009. Detailed results of the joinpoint
regression analyses are given in Supporting Informa-
tion Tables S2 and S3.
No joinpoints were identified for basic analgesics or
very strong analgesics, which both had a small rise in
prescribing over the 9 years in their underlying trend.
However, topical NSAIDs, a basic analgesic, did
increase over time with a sharper increase shown
starting from the quarter (2007q4) before the launch
of the NICE OA guidelines (intervention 4; Fig. 4).
The quarters immediately prior to intervention 1
coincided with significant joinpoints indicating sharp
declines in new all moderate analgesic prescribing,
particularly co-proxamol (from 2004q3; Fig. 5). Cox-2
inhibitors also showed the start of a dramatically sig-
nificant decrease in new prescribing around this time
(Fig. 6). By contrast, new weak analgesic prescribing
and moderate analgesic prescribing other than for
co-proxamol started to significantly increase at this
time. These trends all lasted around 9 months to the
period just after intervention 1, which was also
around the time of intervention 2 (2005q2, 2005q3).
By this time, co-proxamol and Cox-2 inhibitors had
become very infrequently used as new prescriptions.
Co-proxamol had a quarterly prescription incidence of
1/10,000 registered population from 2008 while new
prescribing of Cox-2 inhibitors stabilized at around
8/10,000 by 2007.
The increase in new prescriptions for weak analge-
sics did not last. By 2009, incident prescriptions for
weak analgesics were similar to their 2002 levels.
However, new prescribing of moderate analgesics
excluding co-proxamol started increasing again from
2006q1.
NSAIDs prescribing excluding Cox-2 inhibitors had
one identified joinpoint with prescribing incidence
increasing gradually up to the time of the second inter-
vention (which covered use of low dose NSAIDs)
Figure 4 Incident number of patients per
10,000 registered population prescribed topical
NSAIDs per quarter.
Figure 5 Incident number of patients per
10,000 registered population prescribed mod-
erate analgesics per quarter.
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before falling to initial levels. Prescribing of strong
opioid combinations showed a generally increasing
trend from baseline, which flattened out around the
one joinpoint identified 2007q1.
4. Discussion
This study demonstrated dramatic reductions in new
prescribing of moderate analgesics (especially co-
proxamol) and Cox-2 anti-inflammatory, balanced by
increases in weak analgesic prescribing in the
6 months prior to related specific prescribing guidance
from the MHRA. At the time of the release of the NICE
OA guidelines, there was an increase in the prescribing
of topical NSAIDs. Overall prescribing (repeat plus
new) also followed these trends as shown by the
annual prescription prevalence figures.
MHRA initiatives include direct communiqués with
the GP regarding specific drug safety issues, supple-
mented by press releases and media attention.
Locality-based Primary Care Trust (PCT) prescribing
advisors reinforce these safety messages to doctors
(Braybrook and Walker, 2000). This ‘cascade’ method
may potentially be more effective in delivering the
‘message’ to GPs. This is exemplified by the MHRA
guidance on co-proxamol and Cox-2 prescribing. In
the case of co-proxamol, the MHRA recommended
phasing out its use (intervention 1). The changes in
prescribing trends that started in the period before, and
then became far more substantial during the time
period when guidance on the use of these mediations
was being issued suggests that the changes in prescrib-
ing were related to the guidance (Braybrook and
Walker, 2000). The changes prior to the issuance of
guidance are likely to be related to attention on the
research findings regarding potential adverse events
that would have been available in the medical media,
and these were subsequently reinforced by the MHRA
guidance. A decrease in co-proxamol use at this point
was also reported in a previous study as well as similar
changes in trends for opioid analgesics such as
co-codamol, co-dydramol and codeine (weak analge-
sics; Hawton et al., 2009). The NHS Business Authority
report for PCT prescribing showed a similar decreasing
trend in the use of Cox-2 usage during this period
(NHS Business Authority, 2011). This suggests that our
findings are reflective of prescribing at a national level.
Switching to alternative analgesics appears to have
occurred. A sharp increase in weak analgesic use
occurred in the same time frame as the reduction in
Cox-2 prescribing and co-proxamol. Subsequently,
when weak analgesic use decreased, an increase
in moderate analgesics (excluding co-proxamol)
occurred, which may be explained by alternative mod-
erate analgesia to co-proxamol starting to be used.
Additionally, with the reduction in Cox-2 use, NSAIDs
(excluding Cox-2) showed a slight increase before
falling back gradually to initial levels.
Intervention 4 relates to the NICE OA guidelines.
Prior to these guidelines, there had been debate about
the effectiveness of topical NSAIDs (Bandolier, 2011),
but the main effect appeared to be their increased use.
Other advice related to using opioids (as moderate,
strong or very strong analgesics) or oral NSAIDs
(including Cox-2s) as a third line of therapy, but no
change in their use was seen.
It is possible that NICE guidelines, a summation of
best evidence relating to managing the disease process
in question, are issued at a time when this best evi-
dence pertaining to the condition has already been
enacted by GPs following publication of individual
trial evidence, systematic reviews or specific prescrib-
Figure 6 Incident number of patients per
10,000 registered population prescribed
NSAIDs per quarter.
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ing guidance from regulatory bodies such as the
MHRA. The change in topical NSAID use may have
occurred simply as the result of a ‘green light’ effect,
whereby NICE were lending credence to do more of
what with what was already happening. Previous
studies have identified the limited benefit of guidelines
(Farmer et al., 2008), while others have shown that
guidance with multifaceted aspects, incorporating
social influence and management support can be sub-
stantially more effective (Braybrook and Walker,
2000; Wensing et al., 2010). NICE OA guidelines
relate to managing pain in osteoarthritis. We have
examined the prescribing rates of all general analgesics
(excluding medications used in neuropathic pain),
regardless of the indication. These may be used for
pain relating to conditions other than OA. Conse-
quently, the NICE OA guidelines might appear less
effective than if we had only used a population suffer-
ing with OA-related pain, although in general, mus-
culoskeletal conditions do account for the majority of
consultations for pain in primary care (Jordan et al.,
2010). Prescribing habits may be more profoundly
influenced when the emphasis of the message relates
to ‘risk’ and ‘adverse outcomes’. Doctors are increas-
ingly ‘risk’ aware (MDDUS, 2011), and it is probable
that communications relating to a serious harmful
outcome will be acted upon. When advice, such as
that issued by NICE, focuses more on prescribing that
is designed to ensure a favourable outcome, it may be
that the message carries less gravitas since not follow-
ing the advice will not necessarily end in life-
threatening consequences for the patient.
Our study reports on the temporal associations of
changes in prescribing practices with the release of
national prescribing guidance and changes in prescrib-
ing may have been influenced by other factors, such as
publication of related evidence or production of local
guidelines. For example, Hawton published findings
on the associated risks of using co-proxamol and acci-
dental poisoning in 2003; however, this was 2 years
before the MHRA guidance on its use was issued
(Hawton et al., 2003). Local guidelines on analgesic
use were issued in North Staffordshire as well, but this
was 12 months following the MHRA guidance and did
not include advice on co-proxamol or NSAID use and
do not appear to have changed underlying trends in
prescribing (New Medications Committee, 2006).
A possible limitation of this study is the inclusion of
practices from one area of the United Kingdom, which
is slightly more deprived than England as a whole. The
categorization of analgesics into six groups developed
to rationalize the analysis was undertaken by a rigor-
ous consensus process using practicing GPs and may
include misclassification of drugs into equipotent
groups. However, the similarity of some of our results
with previous work that examined national prescrib-
ing rates indicates that our findings are likely to be
representative of the population in general (Hawton
et al., 2009). We have been unable to examine the
level of analgesics bought over the counter (OTC) by
patients when the changes examined within this study
took place. In the case of basic analgesics and weak
combination opioids, the rates provided are likely to
be an underestimate of the number of people actually
taking these drugs, particularly as they are often
cheaper to purchase OTC for patients who pay for
prescriptions. However, since the amount of medica-
tion that can be bought OTC is limited by regulation,
in those with chronic pain, it may be more cost-
effective to obtain analgesia on prescription (MHRA,
2009). In addition, prescriptions for those aged over
60 years and on low incomes in the United Kingdom
are free. The findings of our study would appear to
support this in that following discontinuation of
co-proxamol, there was an increase in weak analgesics
prescriptions, which contain those drugs that might be
bought OTC. We did not analyse other clinical infor-
mation in the database to interrogate the appropriate-
ness of analgesics prescription in the context of the
MHRA and NICE guidance, rather in this study, we
have undertaken a population level of assessment in
trends, which have assessed how general use has
changed following the directives and intervention.
The changes identified do suggest that GPs are consid-
ering appropriate use of medications. Whether the
appropriateness has improved is an area for further
research but is very complex as it involves many
factors, not just reason for consultation, but also
including concurrent comorbidity, previous OTC and
concomitant prescribed medication, patient prefer-
ence etc., which would have been difficult to evaluate
in this study.
The guidelines and advice assessed in this study
address individual drugs and groups. In recognition of
this, we examined specific drugs when the guidance
related to that particular drug (e.g., co-proxamol) or
group (e.g., cox-2 NSAIDs). However, to examine the
secondary effect of this on other analgesic prescribing,
we used the consensus groups to observe prescribing
trends in terms of drugs GPs might use to substitute for
an equivalent analgesic effect. In particular, did they
use a ‘like for like’ analgesic or change to a lesser or
more potent painkiller. The consensus model was
more suited to this investigation. Additionally, the
consensus exercise recognized that NSAIDs have an
anti-inflammatory element, so they could not fit into
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another analgesic group easily, and often are used in
conjunction with other analgesics where GPs co-
prescribe them.
Our findings suggest that significant changes in pre-
scribing occur at times when national advice and
guidelines are issued to GPs. This is promising in that
the advice would appear to have had the desired
effect, although the level of effectiveness may vary
depending upon the content of, and method of dis-
semination of the information in primary care. Addi-
tionally, future investigation of the relationship
between analgesic prescribing and medications for
comorbid disease such as cardiovascular or respiratory
problems would also help further understand this
complex area of prescribing. Further study of national
guidelines effectiveness in relation to other medica-
tions is required to evaluate the best methods for
delivering prescribing guidance in order to affect posi-
tive change in professional behaviour.
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